Showing 961-970 of 1119 results for "".
- FDA Grants Orphan Drug Designation for Galderma's Trifarotene Molecule to Treat Congenital Ichthyosishttps://practicaldermatology.com/news/20140702-fda_grants_orphan_drug_designation_for_galdermas_trifarotene_molecule_to_treat_congenital_ichthyosis/2459180/The FDA granted orphan drug designation status for Galderma's trifarotene molecule for the treatment of congenital ichthyosis. Based on this decision, Galderma says it pla
- FDA Approves Sivextro to Treat Skin Infections in Adultshttps://practicaldermatology.com/news/20140624-fda_approves_sivextro_to_treat_skin_infections_in_adults/2459192/The FDA approved Sivextro (tedizolid phosphate), a new antibacterial drug, to treat adults with skin infections. Sivextro, which is marketed by Cubist Pharmaceuticals, is approved to treat patients with acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible bact
- Sente, Inc. Awarded European Patent for Active Ingredient in Proprietary Dermal Repair Creamhttps://practicaldermatology.com/news/20140619-sente_inc_awarded_european_patent_for_active_ingredient_in_proprietary_dermal_repair_cream/2459199/Sente has been granted the European Patent for use of a low molecular weight heparan sulfate (HS) for cosmetic products. HS is the most biologically active glycoprotein that is present in all layers of human skin and is the scientific base to Sente Inc's proprietary Dermal Repair Cream. M
- Spain's LETI Laboratories Launches Leading Atopic Skincare Line to U.S. Markethttps://practicaldermatology.com/news/20140617-spains_leti_laboratories_launches_leading_atopic_skincare_line_to_us_market/2459203/DermWORX Professional Skincare and LETI Laboratories, headquartered in Barcelona, Spain, will launch a series of top European dermatological products in the United States. The series includes: LETI's leading dermatology line for atopic skin, AT4, which DermWORX will market to U.S. heal
- Allergan Again Unanimously Rejects Valeant's Revised Unsolicited Proposalhttps://practicaldermatology.com/news/20140610-allergan_again_unanimously_rejects_valeants_revised_unsolicited_proposal/2459212/Allergan has once again rejected the revised unsolicited proposal from Valeant and Pershing Square Capital Management, setting the stage for a lengthy hostile takeover battle. Allergan announced Tuesday that its board of directors, after consulting with its independent financial and legal advisors
- Envy Medical Receives Growth Capital Investment from HCP & Companyhttps://practicaldermatology.com/news/20140604-envy_medical_receives_growth_capital_investment_from_hcp__company/2459218/Chicago-based HCP & Company is providing a growth capital investment to Envy Medical to support sales and marketing initiatives, while also allowing the company to accelerate the development and introduction of new skincare offerings designed to meet the growing demand for healthier skin tone, te
- Cetaphil Launches the Gentle Power Campaignhttps://practicaldermatology.com/news/20140602-cetaphil_launches_the_gentle_power_campaign/2459221/The new Gentle Power Campaign for Cetaphil brands (Galderma) showcases the brand's products and demonstrates how women balance the demands of their day-to-day lives, just as Cetaphil products balance the daily demands on their skin. Stuart Raetzman, chief executive officer of Galderma L
- Valeant And Pershing Square Make Revised Offer For Allergan Contingent On Good Faith Negotiationshttps://practicaldermatology.com/news/20140530-valeant_and_pershing_square_make_revised_offer_for_allergan_contingent_on_good_faith_negotiations/2459224/Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that it is making an offer for Allergan, Inc. (NYSE: AGN) under which each Allergan share would be exchanged for $72.00 in cash and 0.83 shares of Valeant common stock, based on the fully diluted number of
- Michelson Diagnostics Commences New Study with Melanoma Institute of Australiahttps://practicaldermatology.com/news/20140520-michelson_diagnostics_commences_new_study_with_melanoma_institute_of_australia/2459234/The UK based medical device company Michelson Diagnostics has commenced a clinical study to investigate use of Optical Coherence Tomography (OCT) in diagnosing basal cell carcinoma in collaboration with the Melanoma Institute of
- Clinical Trial Finds New Cream Diminishes Symptoms of Psoriasis, Eczemahttps://practicaldermatology.com/news/20140516-clinical_trial_finds_new_cream_diminishes_symptoms_of_psoriasis_eczema/2459237/Findings from an independent study indicate that the antioxidant-based Psorzema Crème formula from derma e® diminishes symptoms of eczema and psoriasis. In an eight-week study, symptomatic participants used Psorzema® Crème, all of whom showed significant improvement in dryness and flak